A Pilot Study Evaluating the Toxicity and Clinical Benefit of Mitogen-activated Protein Kinase (MAPK) Pathway Inhibition Combined With Programmed Cell Death-1 Checkpoint Blockade (Anti-PD1) for the Treatment of BRAF-altered Pediatric Gliomas
This study is testing a combination of targeted cancer medicines and immunotherapy for children and young adults with specific brain or spinal cord tumors. Doctors want to see if combining these treatments can better stop tumors that have returned or are hard to treat.
This study is for children and young adults with certain brain or spinal cord tumors, such as gliomas with specific genetic changes like BRAF alterations or Neurofibromatosis type 1. The tumor may be newly diagnosed, returning, or not responding to previous treatments.
Participants will receive a combination of medications that help block tumor growth and boost the immune system to fight the cancer. The medical team will closely monitor participants to check for side effects and see how well the treatment works.
This study is currently recruiting patients at medical centers in Washington D.C., Chicago, and New York. Your care team can help you figure out if travel to one of these locations is possible.
- 1Tests a combination of targeted therapy and immunotherapy for brain and spinal cord tumors.
- 2Open to children and young adults with specific genetic tumor changes like BRAF or NF1.
- 3Currently recruiting patients at select medical centers in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.